PAION AG
ISIN: DE000A0B65S3 | Ticker: PA8
PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION has started to launch remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia.
In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
2000
Served areaWorldwide
Headcount51
HeadquartersMartinstraße 10-12, 52062 Aachen – Germany
| Date | Trading entity / Person | Association | Trade type | Volume | Average price |
|---|---|---|---|---|---|
| 27.12.22 | Siebert, Gregor | Board | Buy | 24,110.26 € | 27.12.22 |
| 22.12.22 | Dieckow, StB Simone | Close relation | Buy | 500,000.00 € | 22.12.22 |
| 22.12.22 | Fuchs, Anna-Louisa | Close relation | Other | 0.00 € | 22.12.22 |
| 22.12.22 | Fuchs, Mary-Ann | Close relation | Other | 0.00 € | 22.12.22 |
| 21.12.22 | Zeitfracht GmbH & Co. KGaA | Close relation | Buy | 3,607,500.00 € | 21.12.22 |
| 21.12.22 | Schröter, Jasmin | Close relation | Sell | 3,607,500.00 € | 21.12.22 |
71,336,992
IPOFeb. 11, 2005
Designated Sponsor(s)Oddo BHF Corporates & Markets AG
Stock exchange(s)Frankfurt Stock Exchange